Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy
Primary lung cancer is the most common cancer worldwide and is an increasingly common problem. The primary endpoint of this study was; to investigate the effect of radiotherapy dose and neutrophil-lymphocyte ratio (NLR) on overall survival (OS) and progression-free survival (PFS). We retrospectively...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Selcuk University Press
2022-12-01
|
| Series: | Genel Tıp Dergisi |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/download/article-file/2391896 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846092217865732096 |
|---|---|
| author | Hakan Harputluoglu Alper Yeniçeri Ahmet Gulmez |
| author_facet | Hakan Harputluoglu Alper Yeniçeri Ahmet Gulmez |
| author_sort | Hakan Harputluoglu |
| collection | DOAJ |
| description | Primary lung cancer is the most common cancer worldwide and is an increasingly common problem. The primary endpoint of this study was; to investigate the effect of radiotherapy dose and neutrophil-lymphocyte ratio (NLR) on overall survival (OS) and progression-free survival (PFS). We retrospectively examined 99 patients who were stage III A and stage III B at the time of diagnosis, who did not receive surgical treatment, and who received definitive chemoradiotherapy. Data of patients such as sex, age, ECOG status, tumor location, pathological subtype, radiotherapy dose, type of chemotherapy, neutrophil/lymphocyte ratio (NLR), and some biochemical parameters and PFS and OS were included in the study by scanning the patient's files. The radiotherapy cut-off value was accepted as 60 Gray. OS was statistically better in patients who received radiotherapy at doses of 60 Gray and above. When the patients with radiotherapy dose less than 60 Gy and patients with more than 60 Gray were evaluated in two groups, the overall survival was 8,569 ± 1,404 / month and 14,326 ± 1,209 / month, respectively. (p <0.05). When we evaluate the patients based on NLR; It was observed that the overall survival of patients below NLR 4 at the time of diagnosis was statistically significantly better. The overall survival of patients with NLR <4.0 and NLR> 4 was 14.32 ± 1.30 / month and 10.54 ± 1.16 / month, respectively. (p <0.05) |
| format | Article |
| id | doaj-art-bf1f247f0c1243189bb8aa084e70e7d9 |
| institution | Kabale University |
| issn | 2602-3741 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Selcuk University Press |
| record_format | Article |
| series | Genel Tıp Dergisi |
| spelling | doaj-art-bf1f247f0c1243189bb8aa084e70e7d92025-01-02T21:25:28ZengSelcuk University PressGenel Tıp Dergisi2602-37412022-12-0132664665110.54005/geneltip.1107790154Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive ChemoradiotherapyHakan Harputluoglu0Alper YeniçeriAhmet Gulmez1İNÖNÜ ÜNİVERSİTESİİNÖNÜ ÜNİVERSİTESİ, TURGUT ÖZAL TIP MERKEZİPrimary lung cancer is the most common cancer worldwide and is an increasingly common problem. The primary endpoint of this study was; to investigate the effect of radiotherapy dose and neutrophil-lymphocyte ratio (NLR) on overall survival (OS) and progression-free survival (PFS). We retrospectively examined 99 patients who were stage III A and stage III B at the time of diagnosis, who did not receive surgical treatment, and who received definitive chemoradiotherapy. Data of patients such as sex, age, ECOG status, tumor location, pathological subtype, radiotherapy dose, type of chemotherapy, neutrophil/lymphocyte ratio (NLR), and some biochemical parameters and PFS and OS were included in the study by scanning the patient's files. The radiotherapy cut-off value was accepted as 60 Gray. OS was statistically better in patients who received radiotherapy at doses of 60 Gray and above. When the patients with radiotherapy dose less than 60 Gy and patients with more than 60 Gray were evaluated in two groups, the overall survival was 8,569 ± 1,404 / month and 14,326 ± 1,209 / month, respectively. (p <0.05). When we evaluate the patients based on NLR; It was observed that the overall survival of patients below NLR 4 at the time of diagnosis was statistically significantly better. The overall survival of patients with NLR <4.0 and NLR> 4 was 14.32 ± 1.30 / month and 10.54 ± 1.16 / month, respectively. (p <0.05)https://dergipark.org.tr/tr/download/article-file/2391896akciğer kanseridefinitif kemoradyoterapiprognostik belirteçlerlung cancerdefinitive chemoradiotherapyprognostic markers. |
| spellingShingle | Hakan Harputluoglu Alper Yeniçeri Ahmet Gulmez Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy Genel Tıp Dergisi akciğer kanseri definitif kemoradyoterapi prognostik belirteçler lung cancer definitive chemoradiotherapy prognostic markers. |
| title | Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy |
| title_full | Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy |
| title_fullStr | Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy |
| title_full_unstemmed | Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy |
| title_short | Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy |
| title_sort | novel inflammatory prognostic markers in lung cancer patients treated with definitive chemoradiotherapy |
| topic | akciğer kanseri definitif kemoradyoterapi prognostik belirteçler lung cancer definitive chemoradiotherapy prognostic markers. |
| url | https://dergipark.org.tr/tr/download/article-file/2391896 |
| work_keys_str_mv | AT hakanharputluoglu novelinflammatoryprognosticmarkersinlungcancerpatientstreatedwithdefinitivechemoradiotherapy AT alperyeniceri novelinflammatoryprognosticmarkersinlungcancerpatientstreatedwithdefinitivechemoradiotherapy AT ahmetgulmez novelinflammatoryprognosticmarkersinlungcancerpatientstreatedwithdefinitivechemoradiotherapy |